It can limit tumor formation by increasing c-MYC turnover (Huber et al., 2016), or increase the elimination of premalignant and malignant cells through the activation of p53-independent apoptosis pathways (Lee & Sancar, 2011). The gene discussed is TP53; the disease is neoplasm.